MANKIND - IntraDay Trade Analysis with Live Signals

Last Updated Time : 19 Sept 25, 2:16 pm

IntraDay Trade Rating: 4.2

📊 Intraday Trade Analysis for MANKIND

Mankind Pharma shows a strong technical setup for intraday trading today, supported by momentum indicators and volume surge. However, high valuation and a recent dip in quarterly profit suggest a need for disciplined execution.

🔍 Technical & Momentum Overview

RSI (62.5): Bullish, approaching overbought zone — momentum intact but watch for reversal signs.

MACD (19.7): Strong positive crossover, confirming trend continuation.

Volume: Today’s volume (7.36L) is more than double the 1-week average (3.16L), indicating strong intraday interest.

Price Action: Trading above both 50 DMA (₹2,538) and 200 DMA (₹2,476), confirming short-term strength.

Resistance Zone: Approaching ₹2,655–₹2,670 — a breakout above this could trigger momentum toward ₹2,700+.

📈 Fundamental Snapshot

Valuation: P/E of 60.1 and PEG of 7.15 — expensive compared to industry PE of 33.4.

Profitability: EPS of ₹45.1, ROE of 13.9%, ROCE of 15.0% — decent but not exceptional.

Quarterly Profit: Slight dip from ₹382 Cr. to ₹413 Cr. — not alarming but worth monitoring.

Institutional Flow: Mild increase in FII and DII holdings — neutral to positive sentiment.

🎯 Optimal Buy Price for Today

Buy Zone: ₹2,625–₹2,635

Entry near current price with tight stop-loss. Avoid chasing above ₹2,640 unless volume continues to surge.

💰 Exit Levels for Profit-Taking & Stop-Loss

Strategy Price Level (₹) Rationale

Target 1 2,655 Minor resistance zone

Target 2 2,685 Momentum extension target

Stop-Loss 2,610 Below intraday support

🕒 If You Already Hold MANKIND Today

Exit on Weakness

Price drops below ₹2,610 with rising volume.

RSI dips below 58 or MACD flattens.

Exit on Strength

Price nears ₹2,655–₹2,685 with declining volume or bearish divergence.

Watch for reversal candles or lower highs on 5-min chart.

This setup favors breakout scalping with tight stops. Let me know if you'd like to track this live or compare it with other pharma stocks showing similar momentum.

Edit in a page